Royalty Pharma Expects 2026 Portfolio Receipts of $3.5B-$3.55B
Story updates
12:33:20 PM UTC
SquawkNews
Royalty Pharma reported its financial results for the third quarter of 2026, highlighting a 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. Alongside the quarterly results, the company raised its full-year 2026 financial guidance for Portfolio Receipts. CEO and Chairman Pablo Legorreta characterized the performance as excellent, noting the company's continued growth and the decision to increase its outlook.
12:39:59 PM UTC
SquawkNews
Royalty Pharma erhöht Prognose für Portfolioeinnahmen 2026 auf 3.5 bis 3.55 Milliarden US-Dollar
12:43:36 PM UTC
SquawkNews
Royalty Pharma reported third-quarter 2026 Portfolio Receipts of $890 million, up 9% year over year, and raised its full-year Portfolio Receipts guidance to $3.50 billion—$3.55 billion. Net cash provided by operating activities was $686 million. Royalty Receipts grew 9%, supported by several leadin…